Recent advances in periodontal drug delivery systems.

Pragati S, Ashok S, Kuldeep S


Periodontitis, a disease involving supportive structures of the teeth prevails in all groups, ethnicities, races and both genders. The relationship between bacterial plaque and the development of periodontal disease and caries is well established. Antibacterial agents have been used effectively in the management of periodontal infection. The effectiveness of mechanical debridement of plaque and repeated topical and systemic administration of antibacterial agents are limited due to the lack of accessibility to periodontopathic organisms in the periodontal pocket. Systemic administration of drugs leads to therapeutic concentrations at the site of infection, but for short periods of time, forcing repeated dosing for longer periods. Local delivery of antimicrobials has been investigated for the possibility of overcoming the limitations of conventional therapy. The use of sustained release formulations to deliver antibacterials to the site of infection (periodontal pocket) has recently gained interest. These products provide a long-term, effective treatment at the site of infection at much smaller doses. Biodegradable polymers are extensively employed in periodontal drug delivery devices because of their abundant source, lack of toxicity, and high tissue compatibility. A major advantage of natural polymers is that they do not affect periodontal tissue regeneration. Amongst various natural polymers, chitosan, a deacetylated product of chitin is widely used in drug delivery devices. Since it exhibits favourable biological properties such as non-toxicity, biocompatibility, biodegradability and wound healing traits, it has attracted great attention in the pharmaceutical and biomedical fields. The conventional treatment consists of tooth surface mechanical cleaning and root planning, associated or not to the systemic use of high concentrations of antibiotics, but with reduced effectiveness, and adverse effects. The patient compliance to the therapeutic is committed too. In the last decades, the treatment has been optimized for the use of drug delivery systems to the periodontal pocket, with the advantage of delivering the drug in the specific site, sustaining and/or controlling the drug concentration. Recently, the use of new drug delivery systems has been receiving great interest. This review approaches the main delivery systems for the administration of drugs to the periodontal pocket, their usefulness, as well as the advancement of these systems effectiveness in the periodontal therapy.

Keywords : Periodontal diseases; Periodontal pocket; Delivery systems; Periodontal pocket delivery


Periodontal diseases; Periodontal pocket; Delivery systems; Periodontal pocket delivery

Full Text:



Ahuja A, Rahman S, Ali J, Khar RK. Site specific delivery system for treatment of periodontitis. Indian J. of Pha. Sci 2003; 65 (2): 106-112.

Ahuja A, Rahman S, Ali J, Chaudhary R. Effects of dental films containing amoxicillin and metronidazole on periodontal pathogens: microbiological response. Pharmazie 2003; 58 (10): 716-720.

Pihlstrom BL. Periodontal risk assessment, diagnosis and treatment planning. Periodontology 2000; 25 (1): 37-58.

Schwach-Abdellaoui K, Vivien-Casioni N and Gurny R. Local delivery of antimicrobial agents for the treatment of periodontal disease. Eur. J. Pharm. Biopharm. 2000(50): 83–99.

Kim TS, Burklin T, Schacher B, Ratka-Kruger B, Schaecken MT,. Renggli HH,. Fiehn W and Eickholz P. Pharmacokinetic profile of a locally administered doxycycline gel in crevicular fluid, blood, and saliva, J. Periodontol. 2002 (73) :1285–1291.

Issac CY, Jason ., Maria EC, Ruben DS, Caroline BF, Patrice H., Robert L and Shastri VP. A novel polymeric chlorhexidine delivery device for treatment of periodontal disease. Biomaterials 2004; 25 (17): 3743 – 3750.

Dorfer CE. Antimicrobials for the treatment of aggressive periodontitis. Oral disease 2003; 9 (1): 51-53.

Kleinfelder JW, Mueller RE, Lange DE. Fluoroquinolones in the Treatment of Actinobacillus actinomycetemcomitans- Associated periodontitis. J. Periodontology. 2000; 71 (2): 202-208.

Jain N, Gaurav K., Javed S, Iqbal Z, Talegaokar S. Ahmad FJ, Khar RK. Recent approaches for the treatment of periodontitis. Drug. Discov. Today 2008; 1 (21-22): 932-943.

Goodson JM et al. Monolithic tetracycline-containing fibres for controlled delivery to periodontal pockets. J. Periodontol. 1983;(54): 575–579.

Tonetti MS, Piniprato G, Corelli. P. Principles and clinical application of periodontal controlled drug delivery with tetracycline fibers . Int. J. Periodontics and Restorative Dent. 1994 ;14(5): 421- 435.

Vyas SP, Sihorkar V, Mishra V. Controlled and targeted drug delivery strategies towards Intraperiodontal pocket disease. J.Clin Pharm Ther. 2000 :25 (1): 21-42.

Collins AEM. Evaluation of a controlled-release compact containing tetracycline hydrochloride bonded to tooth for the treatment of periodontal. Int. J. Pharm 1989; (51): 103-114.

Tomasi C and Jan LW. Locally delivered doxycycline improves the healing following non surgical periodontal therapy in smokers. J. of Clin. Periodontology. 2004; 31: 589-595.

Kelly HM, Deasy PB, Ziaka E, Cleffey N. Formulation and preliminary in vivo dog studies of a novel drug delivery for the treatment of periodontitis. Int. J. Pharm. 2004; 15 (1): 167 – 183.

Esposito E, Carrota V, Scabbia A, Trombelli L, Antena PD, Menegatti E. Comparative analysis of tetracycline containing dental gels: poloxamer and monoglyceride based formulations. Int. J. Pharm. 1996; (142): 9-23.

Jones SD, Woolfson DA, Brown FA, Michael J, Neill O. Mucoadhesive, syringeable drug delivery systems for controlled application of metronidazole to periodontal pocket. In vitro release kinetics, syringeability, mechanical and and mucoadhesive properties J. Contr. Rel. 2002;49(1): 71-79.

Eskanderi MM, Ozturk OG, Eskandari HG, Balli E and Yilmaz C. Cyanoacrylate adhesive provides efficient local drug delivery. Clin. Orthop Releat Res 2006; (12): 45-55.

Mastiholimath VS, Dandagi PM, Gadad AP, Patil MB and Manvi FV. Formulation and evaluation of ornidazole dental implants for periodontitis . Indian J. Pham Sci. 2006 ;68(1): 68-71.

Vyas SP et al. Preparation, characterization and in vitro antimicrobial activity of metronidazole bearing lectinized liposomes for intra-periodontal pocket delivery. Pharmazie 2001;56:554–560.

Jones MN et al. The interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides. J. Drug Target. 1997; 5: 25–34.

Yoe IC, Poff J, Cortes ME, Simisterra RD, Faris CB, Hildgen P, Langer R, Shastri VP. A novel polymeric chlorhexidine device for treatment of periodontal disease. Biomaterials. 2004 : 25 (17): 3743 –3750.

Dung TH. et al. Chitosan -TPP nanoparticle as a release system of antisense oligonucleotide in the oral environment. J. Nanosci. Nanotechnol 2007; 7: 3695-3699.

Pinon SE. et al. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int. J. Pharm. 2005;294: 217–232

Lindhe J, Westfelt E, Nyman S, Socransky S, Hafajee AD. Long-term effect of surgical/non-surgical treatment of periodontal disease. J Clin. Periodont 2005; 11 (7): 448-458.

Carranza GM and Fermim AC. Clinical Periodontology 9th edn, Saunders; 2004. 676- 683.

Weidner J. A drug delivery system for the treatment of periodontitis. Drug Discov. Today 2001;6 (16): 862-863.

Bromberg LE, Buxton DK, Friden PM. Novel periodontal drug delivery system for treatment of periodontitis. J. Cont. Release 2001; 71 (3): 251-259.

Oliver AS, Andy W, Axel S, Libero I, Giannola GC, Tomasz C, Velten T. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov. Today. 2008 : 13 (5-6): 247-253.

Kaldrandra S, Dongming L, Offenbacher S. Controlled drug release for oral condition by a novel device based on ethylene vinyl acetate (EVA) copolymer. J .Mater Sci .Mater Med. 2002; 13 (1): 53-58.

Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA. Chitosan films and hydrogels of chlorhexidine gluconate on a periodontal pathogen Porphyromonas gingivalis. Int. J. Pharm. 2000; (193):197-203.



  • There are currently no refbacks.


Advanced Research Journals

4/70-71. Black Well HB, AL 30100 2009-2011


Follow @arjournals on Twitter